Nuclotec Remedies Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 26-12-2024
- Paid Up Capital ₹ 7.00 Cr
as on 26-12-2024
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.29 Cr
as on 26-12-2024
- Satisfied Charges ₹ 6.10 Cr
as on 26-12-2024
- Revenue 27.71%
(FY 2021)
- Profit 54.44%
(FY 2021)
- Ebitda -68.22%
(FY 2021)
- Net Worth 238.88%
(FY 2021)
- Total Assets -4.23%
(FY 2021)
About Nuclotec Remedies
The Corporate was formerly known as Boats India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 7.00 Cr.
The company currently has active open charges totaling ₹5.29 Cr. The company has closed loans amounting to ₹6.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Arun Anand and Kanika Anand serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PTC070408
- Company No.
070408
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nuclotec Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Anand  | Director | 03-Jul-1995 | Current |
| Kanika Anand | Director | 01-Sep-2002 | Current |
Financial Performance of Nuclotec Remedies.
Nuclotec Remedies Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 27.71% increase. The company also saw a substantial improvement in profitability, with a 54.44% increase in profit. The company's net worth Soared by an impressive increase of 238.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nuclotec Remedies?
In 2021, Nuclotec Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 25 Mar 2023 | ₹3.37 M | Open |
Others Creation Date: 29 Aug 2007 | ₹4.95 Cr | Open |
Punjab National Bank Creation Date: 23 Dec 2009 | ₹1.60 Cr | Satisfied |
How Many Employees Work at Nuclotec Remedies?
Nuclotec Remedies has a workforce of 110 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nuclotec Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nuclotec Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
